Open Access
Article
Targeting the AMPK pathway for the treatment of Type 2 diabetes
Benoit Viollet1,Louise Lantier1,Jocelyne Devin-Leclerc1,Sophie Hebrard1,Chloe Amouyal1,Remi Mounier1,Marc Foretz1,Fabrizio Andreelli1
1
Institut Cochin, Universite Paris Descartes, CNRS (UMR 8104), Department Endocrinology, Metabolism and Cancer, Paris, France
DOI: 10.2741/3460 Volume 14 Issue 9, pp.3380-3400
Published: 01 January 2009
(This article belongs to the Special Issue New therapeutic approaches for type 2 diabetes)
Abstract

Type 2 diabetes is one of the fastest growing public health problems worldwide, resulting from both genetic factors and inadequate adaptation to environmental changes. It is characterized by abnormal glucose and lipid metabolism due in part to resistance to the actions of insulin in skeletal muscle, liver and fat. AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase, acts as an integrator of regulatory signals monitoring systemic and cellular energy status. The growing realization that AMPK regulates the coordination of anabolic and catabolic metabolic processes represents an attractive concept for type 2 diabetes therapy. Recent findings showing that pharmacological activation of AMPK improves blood glucose homeostasis, lipid profile and blood pressure in insulin-resistant rodents suggest that this kinase could be a novel therapeutic target in the treatment of type 2 diabetes. Consistent with these results, physical exercise and major classes of antidiabetic drugs have recently been reported to activate AMPK. In the present review, we update these topics and discuss the concept of targeting the AMPK pathway for the treatment of type 2 diabetes.

Share and Cite
Benoit Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hebrard, Chloe Amouyal, Remi Mounier, Marc Foretz, Fabrizio Andreelli. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Frontiers in Bioscience-Landmark. 2009. 14(9); 3380-3400.